Member Article

Manchester-based 4D pharma posts first set of results

4D pharma, a Manchester-based pharmaceutical company has announced its maiden set of final results for the period from 10 January 2014 to 31 December 2014.

The stats

The group has reported a loss before tax of £2.38m.

It was successfully admitted to trading on AIM on 18 February 2014 raising £16.55m, it then raised £21.5m in a placing in July 2014.

The analysis

The group’s losses come from its operations in developing new drugs which have yet to come to market.

However the company has had successful development of its first generation programmes, leading clinical trials during 2015.

The comment

Chief executive officer of 4D, Duncan Peyton, said: “We are delighted to have had such a constructive first financial period, which has seen both the evolution of the Group’s initial discovery projects, taking them towards clinical trials in the next 12 months, and the development, through its skilled team of researchers and MicroRx methodology, of the Group’s pipeline of novel live biotherapeutics.

“We remain excited by the prospects for the coming period.”

The summary

A sound start for the company which has reported a pre-tax loss of £2.38m but has clinical trials forthcoming this year.

This was posted in Bdaily's Members' News section by Sophia Taha .